Annual Report

Overview

The report shows Mabpharm's 2024 revenue rising 196.3% to RMB258.2 million, alongside disclosed Scope 1 and Scope 2 emissions of 8,940.76 tons and total energy consumption of 21,570.01 MWh. It reports a 315-person workforce and a materiality survey and matrix. The company also expanded access to medicines through its Gratitude-to-Assistance Program, which supported 620 patients with 6,199 donated doses.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 26 March 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services